Summary
Zoetis Inc.'s 2019 10-K report details a robust year of growth and strategic development in the animal health sector. The company demonstrated strong revenue performance, driven by both its established product lines and new product introductions, particularly in the companion animal segment. Key acquisitions, such as Abaxis, were integrated, contributing to expanded diagnostic capabilities and overall revenue. Zoetis continues to invest significantly in research and development, focusing on product lifecycle innovation and novel solutions for both livestock and companion animals. The company operates across two main segments: the U.S. and International, with each contributing significantly to overall revenue. Zoetis maintains a diversified product portfolio addressing a wide range of animal health needs, from vaccines and parasiticides to anti-infectives and diagnostics. The company's financial health appears solid, with consistent revenue growth and effective management of expenses, though it faces ongoing competitive pressures and the lifecycle management of key products. Investors can find confidence in Zoetis's market leadership, commitment to innovation, and strong financial discipline. The company's focus on expanding its product offerings, entering new markets, and enhancing customer experience positions it well for continued growth in the dynamic animal health industry. Key risks include patent expirations, competition, regulatory changes, and global economic uncertainties, all of which are actively managed by the company.
Financial Highlights
56 data points| Revenue | $6.26B |
| Cost of Revenue | $1.99B |
| Gross Profit | $4.27B |
| SG&A Expenses | $1.64B |
| Interest Expense | $223.00M |
| Net Income | $1.50B |
| EPS (Basic) | $3.14 |
| EPS (Diluted) | $3.11 |
| Shares Outstanding (Basic) | 478.13M |
| Shares Outstanding (Diluted) | 481.79M |
Key Highlights
- 1Zoetis reported strong revenue growth in 2019, with a total of $6.26 billion, representing a 7% increase over 2018, driven by operational growth of 10%.
- 2The companion animal segment experienced significant growth, with revenue up 20% to $3.15 billion, driven by key dermatology products like Apoquel and Cytopoint, and advancements in parasiticides.
- 3The acquisition of Abaxis in July 2018 was integrated, contributing to expanded diagnostic offerings and revenue, particularly in the U.S. companion animal segment.
- 4Research and Development (R&D) expenses increased by 6% to $457 million, reflecting continued investment in innovation and product lifecycle management, supporting a pipeline of new and improved animal health solutions.
- 5The company generated robust net income of $1.5 billion, with diluted earnings per share of $3.11, showcasing effective cost management and operational efficiency.
- 6Zoetis returned significant capital to shareholders through share repurchases, completing a $1.5 billion program and having $1.7 billion remaining under a new authorization as of December 31, 2019, alongside dividend payments.
- 7The company's diverse product portfolio and global operational footprint across two segments (U.S. and International) provide stability, with international revenue growing 3% to $2.97 billion.